{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T05:33:08Z","timestamp":1774157588136,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.euroneuro.2023.02.015","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T02:06:50Z","timestamp":1677118010000},"page":"47-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Silexan for treatment of anxiety and depression in the context of COVID-19"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-8025","authenticated-orcid":false,"given":"Lucie","family":"Bartova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Dold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gernot","family":"Fugger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Weidenauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Rujescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8278-191X","authenticated-orcid":false,"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2023.02.015_bib0001","article-title":"Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited","author":"Bartova","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci"},{"issue":"2","key":"10.1016\/j.euroneuro.2023.02.015_bib0002","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2023.02.015_bib0003","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euroneuro.2022.10.004","article-title":"Psychotropic drug repurposing for COVID-19: a systematic review and meta-analysis","volume":"66","author":"Fico","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.02.015_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.euroneuro.2022.04.006","article-title":"Letter to the editor about the article Psychiatric disorders in post-acute COVID-syndrome 3 (PDPACS): recommendations for health care professionals (Falconi A et\u00a0al., 2022)","volume":"59","author":"Llach","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2023.02.015_bib0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.euroneuro.2022.03.003","article-title":"Psychiatric disorders in Post-acute COVID-syndrome (PDPACS): recommendations for health care professionals","volume":"58","author":"Paez","year":"2022","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2300041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2300041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:05:26Z","timestamp":1760378726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X2300041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":5,"alternative-id":["S0924977X2300041X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.02.015","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Silexan for treatment of anxiety and depression in the context of COVID-19","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}